Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
GoodRx Holdings Inc (NASDAQ: GDRX) closed the day trading at $3.37 down -2.03% from the previous closing price of $3.44. In other words, the price has decreased by -$2.03 from its previous closing price. On the day, 4.67 million shares were traded. GDRX stock price reached its highest trading level at $3.55 during the session, while it also had its lowest trading level at $3.33.
Ratios:
For a better understanding of GDRX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.18. For the most recent quarter (mrq), Quick Ratio is recorded 4.21 and its Current Ratio is at 4.21. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.84.
On December 04, 2024, Mizuho started tracking the stock assigning a Neutral rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on August 09, 2024, while the target price for the stock was maintained at $10.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 15 ’25 when Spectrum Equity VII, L.P. sold 23,771 shares for $4.00 per share. The transaction valued at 95,103 led to the insider holds 0 shares of the business.
Spectrum VII Co-Investment Fun bought 8,569 shares of GDRX for $34,447 on Oct 15 ’25. On Oct 15 ’25, another insider, Spectrum VII Investment Manage, who serves as the Affiliate of the company, bought 15,202 shares for $4.02 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GDRX now has a Market Capitalization of 1170906368 and an Enterprise Value of 1437126528. As of this moment, GoodRx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 36.31, and their Forward P/E ratio for the next fiscal year is 7.39. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.31. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.46 while its Price-to-Book (P/B) ratio in mrq is 1.85. Its current Enterprise Value per Revenue stands at 1.797 whereas that against EBITDA is 10.676.
Stock Price History:
The Beta on a monthly basis for GDRX is 1.21, which has changed by -0.42589438 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, GDRX has reached a high of $6.42, while it has fallen to a 52-week low of $3.31. The 50-Day Moving Average of the stock is -18.58%, while the 200-Day Moving Average is calculated to be -23.95%.
Shares Statistics:
Over the past 3-months, GDRX traded about 4.71M shares per day on average, while over the past 10 days, GDRX traded about 3010030 shares per day. A total of 99.90M shares are outstanding, with a floating share count of 81.43M. Insiders hold about 76.56% of the company’s shares, while institutions hold 16.37% stake in the company. Shares short for GDRX as of 1760486400 were 8252836 with a Short Ratio of 1.75, compared to 1757894400 on 5590466. Therefore, it implies a Short% of Shares Outstanding of 8252836 and a Short% of Float of 9.45.
Earnings Estimates
The company has 12.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.1, with high estimates of $0.11 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.4 and $0.34 for the fiscal current year, implying an average EPS of $0.37. EPS for the following year is $0.46, with 12.0 analysts recommending between $0.51 and $0.39.
Revenue Estimates
13 analysts predict $194.51M in revenue for . The current quarter. It ranges from a high estimate of $197.48M to a low estimate of $192.54M. As of . The current estimate, GoodRx Holdings Inc’s year-ago sales were $195.25MFor the next quarter, 13 analysts are estimating revenue of $197.6M. There is a high estimate of $202.12M for the next quarter, whereas the lowest estimate is $194.1M.
A total of 15 analysts have provided revenue estimates for GDRX’s current fiscal year. The highest revenue estimate was $804.6M, while the lowest revenue estimate was $794.01M, resulting in an average revenue estimate of $797.96M. In the same quarter a year ago, actual revenue was $792.32MBased on 15 analysts’ estimates, the company’s revenue will be $840.24M in the next fiscal year. The high estimate is $871.41M and the low estimate is $816.1M.
